Want to see IN:STAR full AI Analyst Report?
STAR Stock Chart & Stats
₹950.75
-₹13.60(-1.99%)
At close: 4:00 PM EST
₹950.75
-₹13.60(-1.99%)
Day’s Range― - ―
52-Week Range₹769.60 - ₹1,231.45
Previous CloseN/A
Volume639.08K
Average Volume (3M)12.54K
Market Cap
₹100.77B
Enterprise Value₹117.47B
Total Cash (Recent Filing)₹2.27B
Total Debt (Recent Filing)₹18.44B
Price to Earnings (P/E)18.1
Beta0.86
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.41%
Share Statistics
EPS (TTM)43.13
Shares Outstanding92,172,714
10 Day Avg. Volume13,417
30 Day Avg. Volume12,536
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)2.78
Price to Sales (P/S)1.78
P/FCF Ratio71.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)71.07
Revenue Forecast (FY)₹57.61B
Bulls Say, Bears Say
Bulls Say
Profitability TurnaroundThe company moved from losses in 2022–2024 to solid profits in 2025–2026, with gross margin around 36% and net margin ~11%. This turnaround indicates restored operating leverage and execution, supporting sustainable earnings power if margins are maintained.
Balance Sheet RecoveryMaterial debt reduction and rising equity improved financial resilience: lower leverage and an ROE rebound to ~18% reduce refinancing risk and increase flexibility for investments or acquisitions, strengthening medium-term credit profile and strategic optionality.
Revenue Growth & Market ReachConsistent revenue expansion across regulated and semi-regulated markets reflects diversified commercial channels and finished-dosage capabilities. Stable top-line growth supports margin recovery and reduces single-market concentration risks over the next several quarters.
Bears Say
Cash Flow QualityFree cash flow is volatile and weakened in 2026, with FCF only about 22% of net income and a ~50% YoY drop. That weak conversion limits internal funding for capex, dividends or debt paydown and raises execution risk if cash generation slips again.
Elevated Absolute DebtAlthough leverage metrics improved, the company still carries significant absolute debt and only recently recovered from stressed profitability. This leaves less buffer against shocks and makes the business more sensitive to interest or operational setbacks over the medium term.
Historical Profit VolatilityPast multi-year losses and margin swings signal execution and cycle vulnerability in generics: product approvals, pricing or facility utilization shifts can reverse gains. The recurrence risk of margin pressure undermines confidence in consistent medium-term profitability.
Strides Pharma Science Ltd News
STAR FAQ
What was Strides Pharma Science Ltd’s price range in the past 12 months?
Strides Pharma Science Ltd lowest stock price was ₹769.60 and its highest was ₹1231.45 in the past 12 months.
What is Strides Pharma Science Ltd’s market cap?
Strides Pharma Science Ltd’s market cap is ₹100.77B.
When is Strides Pharma Science Ltd’s upcoming earnings report date?
Strides Pharma Science Ltd’s upcoming earnings report date is Aug 05, 2026 which is in 34 days.
How were Strides Pharma Science Ltd’s earnings last quarter?
Strides Pharma Science Ltd released its earnings results on May 18, 2026. The company reported ₹13.77 earnings per share for the quarter, beating the consensus estimate of N/A by ₹13.77.
Is Strides Pharma Science Ltd overvalued?
According to Wall Street analysts Strides Pharma Science Ltd’s price is currently Overvalued.
Does Strides Pharma Science Ltd pay dividends?
Strides Pharma Science Ltd pays a Annually dividend of ₹4 which represents an annual dividend yield of 0.41%. See more information on Strides Pharma Science Ltd dividends here
What is Strides Pharma Science Ltd’s EPS estimate?
Strides Pharma Science Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Strides Pharma Science Ltd have?
Strides Pharma Science Ltd has 92,172,714 shares outstanding.
What happened to Strides Pharma Science Ltd’s price movement after its last earnings report?
Strides Pharma Science Ltd reported an EPS of ₹13.77 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.316%.
Which hedge fund is a major shareholder of Strides Pharma Science Ltd?
Currently, no hedge funds are holding shares in IN:STAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Strides Pharma Science Ltd
Strides Pharma Science Limited is a pharmaceutical company that focuses on the development, production, and worldwide commercialization of medicinal products. Its extensive global footprint spans Africa, Australia, North America, Europe, Asia, India, and various other international markets. The company's operations are structured into two distinct segments: Pharmaceutical and Biopharmaceutical. It provides a diverse range of generic pharmaceuticals, available in multiple formats including tablets, hard and soft gelatin capsules, sachets, liquids, nasal sprays, powders, solids, ointments, and creams. Furthermore, Strides Pharma Science creates branded generic offerings for treating chronic ailments such as women's health issues, central nervous system disorders, cardiovascular conditions, diabetes, dermatological concerns, and probiotic support, marketed under brands like Renerve, Unibrol, Combiart, Duotab, and Vitafer. For institutional business, the company supplies drugs targeting infectious diseases, including anti-retrovirals, anti-malarials, anti-tuberculosis, and Hepatitis treatments. Incorporated in 1990, the company is headquartered in Bengaluru, India. It was formerly known as Strides Shasun Limited before adopting its current name in July 2018.
Technical Analysis
Aurobindo Pharma Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Laurus Labs Ltd.
―
Piramal Pharma Limited
―
Sun Pharmaceutical Industries Limited
―






